Point72 Asset Management L.P. Makes New $526,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Point72 Asset Management L.P. acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,596,344 shares of the company’s stock, valued at approximately $526,000. Point72 Asset Management L.P. owned about 0.85% of Tonix Pharmaceuticals as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock worth $650,000 after buying an additional 1,855,907 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Tonix Pharmaceuticals by 5,932.3% in the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after purchasing an additional 1,635,119 shares in the last quarter. Northern Trust Corp purchased a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $162,000. PFG Investments LLC purchased a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $72,000. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $40,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Insider Buying and Selling at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 4,000 shares of Tonix Pharmaceuticals stock in a transaction on Thursday, May 15th. The shares were bought at an average price of $21.55 per share, with a total value of $86,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 4,005 shares of the company’s stock, valued at approximately $86,307.75. This trade represents a 80,000.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.03% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on TNXP shares. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Noble Financial reiterated an “outperform” rating and issued a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP opened at $26.40 on Friday. The company has a 50-day simple moving average of $19.98 and a 200-day simple moving average of $21.24. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $193.38 million, a PE ratio of -0.01 and a beta of 1.63. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $6.76 and a 52-week high of $624.00.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Monday, May 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.43 million during the quarter, compared to analysts’ expectations of $2.55 million. Equities research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.